Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Pac-Man 99 removed from Nintendo Switch Online
Fans hail 'dark' storyline as new Final Fantasy title released
Amazon’s newest Kindle is a great addition to your library
Apple moved the 'end call' button in iOS 17 for some reason
How to Get Cyberpunk 2077 Phantom Liberty Early Access
Mark Zuckerberg Went Beast Mode in His First Jiu-Jitsu Match
Alix Earle elevates pajamas with classy streetwear look on her day out: 'A girl who can do both'
Parents can now stalk their kids with new Uber features